Longitudinal Retinal Changes in MOGAD.
Oertel FC., Sotirchos ES., Zimmermann HG., Motamedi S., Specovius S., Asseyer ES., Chien C., Cook L., Vasileiou E., Filippatou A., Calabresi PA., Saidha S., Pandit L., D'Cunha A., Outteryck O., Zéphir H., Pittock S., Flanagan EP., Bhatti MT., Rommer PS., Bsteh G., Zrzavy T., Kuempfel T., Aktas O., Ringelstein M., Albrecht P., Ayzenberg I., Pakeerathan T., Knier B., Aly L., Asgari N., Soelberg K., Marignier R., Tilikete CF., Cobo Calvo A., Villoslada P., Sanchez-Dalmau B., Martinez-Lapiscina EH., Llufriu S., Green AJ., Yeaman MR., Smith TJ., Brandt AU., Chen J., Paul F., Havla J., with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group None.
OBJECTIVE: Patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro-axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON-independent retinal atrophy can be detected in MOGAD. METHODS: Eighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD: N = 66 and HCs: N = 103) and (2) Cirrus high-definition OCT (MOGAD: N = 14 and HCs: N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified. RESULTS: At baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD-ON) compared with MOGAD eyes without a history of ON (MOGAD-NON) and HCs (p